We are live on ! Find out more
FCMI

Foresite Capital Management IV Portfolio holdings

AUM $237M
1-Year Est. Return 107.53%
This Fund
S&P 500
This Quarter Est. Return
+41.92%
1 Year Est. Return
+107.53%
3 Year Est. Return
+149.4%
5 Year Est. Return
+13.8%
10 Year Est. Return
–
AUM
$443M
AUM Growth
+$238M
Cap. Flow
+$159M
Cap. Flow %
35.82%
Top 10 Hldgs %
94.78%
Holding
19
New
7
Increased
1
Reduced
3
Closed
4

Top Buys

Rank Stock Value
1
RLAY icon
Relay Therapeutics
RLAY
+$81.6M
2
NRIX icon
Nurix Therapeutics
NRIX
+$59.2M
3
ALXO icon
ALX Oncology
ALXO
+$38.3M
4
ABUS icon
Arbutus Biopharma
ABUS
+$10.1M
5
PNT
POINT Biopharma Global Inc. Common Stock
PNT
+$4.77M

Top Sells

Rank Stock Value
1
FULC icon
Fulcrum Therapeutics
FULC
+$20.7M
2
PCVX icon
Vaxcyte
PCVX
+$6.17M
3
CBAY
Cymabay Therapeutics
CBAY
+$5.65M
4
ORIC icon
Oric Pharmaceuticals
ORIC
+$4.22M
5
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$635K

Sector Composition

Rank Sector Weight
1 Healthcare 99.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RLAY icon
1
Relay Therapeutics
RLAY
$4.1B
$91.1M 20.55%
+2,139,380
New +$81.6M
NRIX icon
2
Nurix Therapeutics
NRIX
$2.41B
$82M 18.48%
+2,348,014
New +$59.2M
KROS icon
3
Keros Therapeutics
KROS
$199M
$54.5M 12.29%
1,412,705
-15,366
-1% -$609K
KURA icon
4
Kura Oncology
KURA
$800M
$40.1M 9.04%
1,307,982
– –
ALXO icon
5
ALX Oncology
ALXO
$261M
$36.7M 8.29%
+973,514
New +$38.3M
CYTK icon
6
Cytokinetics
CYTK
$10.5B
$36.2M 8.16%
1,672,292
+65,000
+4% +$1.52M
GBIO
7
DELISTED
Generation Bio
GBIO
$26.5M 5.98%
85,794
– –
PCVX icon
8
Vaxcyte
PCVX
$7.81B
$23M 5.19%
465,821
-155,000
-25% -$6.17M
MYOK
9
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$17.2M 3.89%
126,492
– –
CBAY
10
DELISTED
Cymabay Therapeutics
CBAY
$12.9M 2.92%
1,787,094
-1,056,799
-37% -$5.65M
ABUS icon
11
Arbutus Biopharma
ABUS
$857M
$10.4M 2.35%
+3,332,616
New +$10.1M
VYGR icon
12
Voyager Therapeutics
VYGR
$183M
$5.51M 1.24%
516,751
– –
PNT
13
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$5.03M 1.14%
+350,000
New +$4.77M
PANA.U
14
DELISTED
Panacea Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third
PANA.U
$1.8M 0.41%
+150,000
New +$1.73M
ACRS icon
15
Aclaris Therapeutics
ACRS
$726M
$372K 0.08%
+144,874
New +$324K
FULC icon
16
Fulcrum Therapeutics
FULC
$273M
– –
-1,133,948
Closed -$20.7M
ORIC icon
17
Oric Pharmaceuticals
ORIC
$1.15B
– –
-125,000
Closed -$4.22M
TVTX icon
18
Travere Therapeutics
TVTX
$5.2B
– –
-30,000
Closed -$612K
DRNA
19
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-25,000
Closed -$635K

Similar funds

BCM
Birmingham Capital Management Birmingham, Alabama $237M AUM 32.7% 1-Year Est. Return
AG
ASO Group Road Town $237M AUM
FL
FreeGulliver LLC New Orleans, Louisiana $237M AUM 21.92% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
MFA
Millington Financial Advisors Naperville, Illinois $237M AUM 22.22% 1-Year Est. Return
TCM
Tekne Capital Management New York $237M AUM 62.98% 1-Year Est. Return
WW
Windle Wealth Oklahoma City, Oklahoma $237M AUM 22.79% 1-Year Est. Return
CB
CNB Bank Clearfield, Pennsylvania $238M AUM 26.55% 1-Year Est. Return

Foresite Capital Management IV's Q3 2020 Portfolio in Review

As of Q3 2020, Foresite Capital Management IV held 19 positions worth $443M, up 116% from $205M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

Foresite Capital Management IV deployed $159M of net new capital in Q3 2020, opening 7 new positions and adding to 1 existing holding. Its largest new stake was Relay Therapeutics: 2,139,380 shares worth $91.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Vaxcyte, an estimated $6.17M trimmed.

  • Foresite Capital Management IV's largest Q3 2020 buy was Relay Therapeutics: 2,139,380 shares worth $91.1M.
  • Foresite Capital Management IV added most to Cytokinetics in Q3 2020, an estimated $1.52M increase.
  • Foresite Capital Management IV's biggest Q3 2020 reduction was Vaxcyte, cutting an estimated $6.17M.
  • Foresite Capital Management IV fully exited Fulcrum Therapeutics in Q3 2020, selling an estimated $20.7M.
  • Foresite Capital Management IV's ten largest holdings make up 95% of its $443M portfolio in Q3 2020.
  • Foresite Capital Management IV opened 7 new positions and closed 4 in Q3 2020.
  • Foresite Capital Management IV's portfolio value rose 116% quarter-over-quarter to $443M.

Based on Foresite Capital Management IV's 13F filing for Q3 2020, filed 13 Nov 2020.